CTOs on the Move

Paige.AI

www.paige.ai

 
PAIGE is being built by a dedicated team of Machine Learning experts and pathologists from the leading cancer center in the US and experienced business leadership.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.paige.ai
  • 3 East 71st Street Suite 6B
    New York, NY USA 10021
  • Phone: 212.687.8080

Executives

Name Title Contact Details

Funding

Paige.AI raised $25M on 02/06/2018
Paige.AI raised $45M on 12/18/2019
Paige.AI raised $20M on 07/13/2020
Paige.AI raised $100M on 01/14/2021

Similar Companies

Pacificord

Pacificord is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IVFCRYO

Ensuring safe and secure management of reproductive specimens world wide. Tank failures happen. Specimens don’t have to be lost because of that. We can help.

The Public Health Company

PHC empowers organizations to proactively manage infectious disease risk through global disease forecasting, risk analysis, and practical guidance. PHC was founded by Dr. Charity Dean, and employs a world-class team of public health professionals, tech...

Cleartrails

Cleartrails is a Villa Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity. In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics. The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.